From the Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.
Clin Nucl Med. 2019 Sep;44(9):e519-e521. doi: 10.1097/RLU.0000000000002724.
A 57-year-old man with stage IIIB malignant melanoma of unknown primary presented for pretherapy FDG PET/CT that demonstrated metastatic left cervical lymph node with no other site of involvement. Following left neck dissection, nivolumab was initiated. Follow-up FDG PET/CT 3 months after initiation of nivolumab demonstrated extensive radiotracer-avid chest lymphadenopathy and multiple bone lesions. Ultrasound-guided endobronchial biopsy of the mediastinal lymph nodes demonstrated sarcoidosis.
一位 57 岁男性患有未知原发灶的 IIIB 期恶性黑色素瘤，在进行治疗前 FDG PET/CT 检查时发现左侧颈部淋巴结转移，无其他部位受累。行左颈部淋巴结清扫术后，开始使用纳武利尤单抗治疗。纳武利尤单抗治疗开始 3 个月后复查 FDG PET/CT 显示广泛摄取放射性示踪剂的胸部淋巴结肿大和多处骨病变。纵隔淋巴结经超声引导支气管内活检显示为结节病。
